[16] However, a meta-analysis of 48 randomized controlled trials demonstrated that SGLT2 inhibitors significantly increased total cholesterol, LDL-cholesterol, non-HDL-cholesterol, and HDL-cholesterol, and decreased TG levels in patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.